PE20040924A1 - Bromhidrato de escitalopram y un metodo para su preparacion - Google Patents
Bromhidrato de escitalopram y un metodo para su preparacionInfo
- Publication number
- PE20040924A1 PE20040924A1 PE2004000013A PE2004000013A PE20040924A1 PE 20040924 A1 PE20040924 A1 PE 20040924A1 PE 2004000013 A PE2004000013 A PE 2004000013A PE 2004000013 A PE2004000013 A PE 2004000013A PE 20040924 A1 PE20040924 A1 PE 20040924A1
- Authority
- PE
- Peru
- Prior art keywords
- disorders
- bromhydrate
- compound
- escitalopram
- treatment
- Prior art date
Links
- 229960004341 escitalopram Drugs 0.000 title abstract 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 206010029333 Neurosis Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 229960001653 citalopram Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011221 initial treatment Methods 0.000 abstract 1
- 208000015238 neurotic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE AL COMPUESTO: ESCITALOPRAM DE FOMULA (S)-1-[3-(DIMETILAMINO)PROPIL]-1-(4-FLUORFENIL)-1,3-DIHIDRO-5-ISOBENZOFURANCARBONITRILO, QUE VIENE A SER EL ENANTIOMERO S DEL COMPUESTO CITALOPRAM, REFIRIENDOSE ESPECIFICAMENTE A SU SAL DE BROMHIDRATO, EN SU FORMA SOLIDA-CRISTALINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA QUE CONTIENE BROMHIDRATO DE ESCITALOPRAM Y UNO O MAS PORTADORES Y DILUYENTES FARMACEUTICAMENTE ACEPTABLES. ESTE COMPUESTO ES UN INHIBIDOR DE LA REABSORCION DE SEROTONINA DE ACCION CENTRAL Y ES UTIL PARA EL TRATAMIENTO DE LA DEPRESION, QUE ABARCA EL TRATAMIENTO DE PACIENTES QUE NO RESPONDIERON AL TRATAMIENTO INICIAL CON SSRI CONVENCIONALES, TRASTORNOS NEUROTICOS, TRASTORNOS DE ESTRES AGUDO, DESORDENES DE LA ALIMENTACION COMO BULIMIA, ANOREXIA Y OBESIDAD, DISTIMIA, SINDROME PREMENSTRUAL, TRASTORNOS COGNITIVOS, TRASTORNOS DE CONTROL DE IMPULSOS, TRASTORNOS DE HIPERACTIVIDAD Y FALTA DE ATENCION Y ABUSO DE DROGAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200202005 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040924A1 true PE20040924A1 (es) | 2004-12-11 |
Family
ID=32668635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000013A PE20040924A1 (es) | 2002-12-23 | 2004-01-05 | Bromhidrato de escitalopram y un metodo para su preparacion |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20040167209A1 (es) |
| EP (1) | EP1578738B1 (es) |
| JP (2) | JP4658613B2 (es) |
| KR (1) | KR20050086933A (es) |
| CN (1) | CN100349885C (es) |
| AR (1) | AR042652A1 (es) |
| AT (1) | ATE388947T1 (es) |
| AU (1) | AU2003287919B2 (es) |
| BR (1) | BR0317623A (es) |
| CA (1) | CA2511142A1 (es) |
| CY (1) | CY1107451T1 (es) |
| DE (1) | DE60319739T2 (es) |
| DK (1) | DK1578738T3 (es) |
| EA (1) | EA013116B1 (es) |
| EG (1) | EG24729A (es) |
| ES (1) | ES2298595T3 (es) |
| IL (1) | IL169125A0 (es) |
| IS (1) | IS2654B (es) |
| ME (1) | MEP5808A (es) |
| MX (1) | MXPA05005772A (es) |
| MY (1) | MY135468A (es) |
| NO (1) | NO20053595L (es) |
| NZ (1) | NZ540281A (es) |
| PE (1) | PE20040924A1 (es) |
| PL (1) | PL378275A1 (es) |
| PT (1) | PT1578738E (es) |
| RS (1) | RS51092B (es) |
| TW (1) | TW200501943A (es) |
| UA (1) | UA80170C2 (es) |
| UY (1) | UY28148A1 (es) |
| WO (1) | WO2004056791A1 (es) |
| ZA (1) | ZA200504109B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| EP1578738B1 (en) * | 2002-12-23 | 2008-03-12 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
| CA2558198A1 (en) * | 2004-03-05 | 2005-09-15 | H. Lundbeck A/S | Crystalline composition containing escitalopram oxalate |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| EP1954257A4 (en) * | 2005-10-14 | 2009-05-20 | Lundbeck & Co As H | METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION |
| KR20080075113A (ko) * | 2005-10-14 | 2008-08-14 | 하. 룬트벡 아크티에 셀스카브 | 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형 |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| TWI399375B (zh) * | 2006-07-11 | 2013-06-21 | Mitsubishi Tanabe Pharma Corp | 嗎啉化合物之鹽 |
| WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
| FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
| CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
| PL3694843T3 (pl) * | 2017-10-09 | 2022-06-20 | Hasleton, Mark | Nowa sól i nowe stałe postacie escitalopramu |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US34712A (en) * | 1862-03-18 | James h | ||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| WO2000023431A1 (en) * | 1998-10-20 | 2000-04-27 | H. Lundbeck A/S | Method for the preparation of citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| HK1043129B (zh) * | 1999-10-25 | 2004-10-21 | H‧隆德贝克有限公司 | 西酞普蘭的製備方法 |
| US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
| JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
| CA2353693C (en) * | 2000-08-10 | 2003-07-22 | H. Lundbeck A/S | Pharmaceutical composition containing citalopram |
| BR0115908B1 (pt) * | 2000-12-04 | 2011-10-04 | processo para a produção de ésteres de ácido graxo. | |
| JP2004527551A (ja) * | 2001-05-01 | 2004-09-09 | ハー・ルンドベック・アクチエゼルスカベット | エナンチオ純粋なエスシタロプラムの使用方法 |
| AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
| EP1578738B1 (en) * | 2002-12-23 | 2008-03-12 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
| US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Ceased
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en not_active Ceased
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040924A1 (es) | Bromhidrato de escitalopram y un metodo para su preparacion | |
| NO20085009L (no) | Nye anvendelser av escitalopram | |
| ES2195554T3 (es) | Metodo para la preparacion de citalopram. | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| YU68802A (sh) | Kristalna baza citaloprama | |
| DE60200492D1 (de) | Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| MXPA05008652A (es) | Uso del enantiomero (1s,2r) de milnacipran para la preparacion de un medicamento. | |
| RU2009113038A (ru) | Комбинированная лекарственная терапия для лечения ожирения | |
| BRPI0610037A2 (pt) | derivados de dihidrobenzofurano e uso dos mesmos | |
| IL183064A0 (en) | Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition | |
| EA200001218A1 (ru) | Комбинационная терапия для лечения резистентной депрессии | |
| AR033308A1 (es) | Uso de escitalopram enantiomericamente puro | |
| UY28945A1 (es) | Derivados de pirrolopiridina | |
| BRPI0610028A2 (pt) | combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos | |
| ATE451361T1 (de) | Materialien und methoden zur behandlung von koagulationsstörungen | |
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| UA84692C2 (ru) | Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения | |
| WO2004100940B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| AR045314A1 (es) | Composiciones farmaceuticas de analepticos y antidepresivos | |
| AR048134A1 (es) | La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial | |
| BRPI0408732A (pt) | processo para a preparação de um ciano-isobenzofurano | |
| BRPI0415899A (pt) | usos de um composto, e de um antagonista de receptor de h3, agonista inverso ou agonista parcial, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto | |
| JP2007502785A5 (es) | ||
| MXPA04001030A (es) | Proceso para la preparacion de isobenzofuranos 5-sustituidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |